Please assess the completion status of the following clinical trial:

Trial Title: Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Clinical Inclusion Criteria:~1. Signs \& symptoms consistent w/ the diagnosis of acute anterior circulation ischemic stroke~2. Age 18-90 years~3. Baseline NIHSSS is ≥ 6 and remains ≥6 immediately prior to randomization~4. Endovascular treatment can be initiated (femoral puncture) between 6 and 16 hours of stroke onset. Stroke onset is defined as the time the patient was last known to be at their neurologic baseline (wake-up strokes are eligible if they meet the above time limits).~5. modified Rankin Scale less than or equal to 2 prior to qualifying stroke (functionally independent for all ADLs)~6. Patient/Legally Authorized Representative has signed the Informed Consent form.~Clinical Exclusion Criteria:~1. Other serious, advanced, or terminal illness (investigator judgment) or life expectancy is less than 6 months.~2. Pre-existing medical, neurological or psychiatric disease that would confound the neurological or functional evaluations~3. Pregnant~4. Unable to undergo a contrast brain perfusion scan with either MRI or CT~5. Known allergy to iodine that precludes an endovascular procedure~6. Treated with tPA \>4.5 hours after time last known well~7. Treated with tPA 3-4.5 hours after last known well AND any of the following; age \>80, current anticoagulant use, history of diabetes or prior stroke, NIHSS \>25~8. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR \> 3 (recent use of one of the new oral anticoagulants is not an exclusion if estimated GFR \> 30 ml/min).~9. Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS~10. Baseline blood glucose of \<50mg/dL (2.78 mmol) or \>400mg/dL (22.20 mmol)~11. Baseline platelet count \< 50,000/uL~12. Severe, sustained hypertension (Systolic BP \>185 mmHg or Diastolic BP \>110 mmHg)~13. Current participation in another investigational drug or device study~14. Presumed septic embolus; suspicion of bacterial endocarditis~15. Clot retrieval attempted using a neurothrombectomy device prior to 6 hrs from symptom onset~16. Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.~Neuroimaging Inclusion Criteria:~1. ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial; with or without tandem MCA lesions) by MRA or CTA~   AND~2. Target Mismatch Profile on CT perfusion or MRI (ischemic core volume is \< 70 ml, mismatch ratio is \>/= 1.8 and mismatch volume\* is \>/= 15 ml)~Alternative neuroimaging inclusion criteria (if perfusion imaging or CTA/MRA is technically inadequate):~A) If CTA (or MRA) is technically inadequate:~Tmax\>6s perfusion deficit consistent with an ICA or MCA-M1 occlusion AND Target Mismatch Profile (ischemic core volume is \< 70 ml, mismatch ratio is \>1.8 and mismatch volume is \>15 ml as determined by RAPID software)~B) If MRP is technically inadequate:~ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial; with or without tandem MCA lesions) by MRA (or CTA, if MRA is technically inadequate and a CTA was performed within 60 minutes prior to the MRI) AND DWI lesion volume \< 25 ml~C) If CTP is technically inadequate:~Patient can be screened with MRI and randomized if neuroimaging criteria are met.~Neuroimaging Exclusion Criteria:~1. ASPECTS score \<6 on non-contrast CT (if patient is enrolled based on CT perfusion criteria)~2. Evidence of intracranial tumor (except small meningioma) acute intracranial hemorrhage, neoplasm, or arteriovenous malformation~3. Significant mass effect with midline shift~4. Evidence of internal carotid artery dissection that is flow limiting or aortic dissection~5. Intracranial stent implanted in the same vascular territory that precludes the safe deployment/removal of the neurothrombectomy device~6. Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- endovascular thrombectomy therapy (Type: ACTIVE_COMPARATOR): Treatment with one or more thrombectomy devices (only the devices listed in this protocol are approved for use in DEFUSE 3) plus standard medical therapy for patients who have evidence of an ICA or MCA M1 occlusion and a Target Mismatch Profile.~Devices approved for use in DEFUSE 3:~* Trevo Retriever~* Solitaire™ FR Revascularization Device~* Penumbra thrombectomy system~* Covidien MindFrame Capture Revascularization Device
- Medical Management (Type: NO_INTERVENTION): standard medical therapy alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy